Deep Breaths: Updates from CHEST

Selection among therapies for severe asthma can be challenging, but there are 'treatable traits' clinicians can use to better predict which patients will have a favorable response.

Personalized management strategies for patients with severe asthma should consider patient history, lifestyle, triggers, comorbidities, symptoms, and patient technique, compliance, and education, as these three patient cases show.

Selection among therapies for severe asthma can be challenging, but there are 'treatable traits' clinicians can use to better predict which patients will have a favorable response.

Personalized management strategies for patients with severe asthma should consider patient history, lifestyle, triggers, comorbidities, symptoms, and patient technique, compliance, and education, as these three patient cases show.

To help us address the current lack of awareness of uncontrolled or symptomatic asthma in all stages of the disease, Dr. Xavier Soler is joined by Dr. Nicola Hanania, Associate Professor of Pulmonary Medicine and Director of the Airway Clinical Research Center at Baylor College of Medicine in Houston, Texas. Together, they’ll discuss how we can better recognize and treat our patients with uncontrolled asthma.

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

Recent advances in asthma therapy have included several new biologic agents that modify Th2-inflammatory pathways. Treatment guidelines have provided a framework for the treatment of patients with Th2-mediated allergic asthma. However, approximately half of asthmatic patients do not fall within the Th2 inflammatory paradigm. Cinicians must be knowledgeable of treatment options and the role of potential novel therapies for this subgroup of patients.

Severe asthma is a heterogenous disease, and patients present with a variety of clinical histories, physiologic changes (beyond changes in forced expiratory volume in one second), and airway inflammation. That’s why Dr. Sandra Adams is joined by Dr. Linda Rogers, Clinical Director of the Asthma Program at the Icahn School of Medicine at Mount Sinai, to discuss how we can better differentiate difficult-to-control and severe or refractory types of asthma.

The presentation and management of pediatric asthma differs by age group and from adults. And since the management of uncontrolled asthma in children is especially challenging, pediatricians and other specialists need to learn how to incorporate recent diagnostic and treatment developments into their practice.

Clinicians must be knowledgeable of the inflammatory, immunologic, and pathobiologic features leading to severe asthma. Clinicians must also have knowledge of severe asthma phenotypes and the implications for treating patients.

The care team supporting a patient with mycobacterium avium complex, or MAC, lung disease is just as important as the treatment itself. Joining Dr. David Griffith to discuss how we can provide optimal treatment using established guideline-based strategies all while protecting patients’ quality of life are Dr. Tim Aksamit and pulmonary nurse practitioner Amy Levinger.

For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.

The care team supporting a patient with mycobacterium avium complex, or MAC, lung disease is just as important as the treatment itself. Joining Dr. David Griffith to discuss how we can provide optimal treatment using established guideline-based strategies all while protecting patients’ quality of life are Dr. Tim Aksamit and pulmonary nurse practitioner Amy Levinger.

For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.

With uncontrolled asthma placing such a tremendous burden on our patients and our society, how can we use the latest treatment guidelines to help alleviate that burden? Dr. Matt Hegewald is here to talk about the new and emerging guideline-based treatments for uncontrolled asthma, like long-acting muscarinic antagonists.

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.